What Is PIH in Pregnancy: Symptoms, Risks & Treatment

Pregnancy-induced hypertension, commonly shortened to PIH, refers to high blood pressure that develops for the first time after 20 weeks of pregnancy in someone who previously had normal readings. Blood pressure at or above 140/90 mmHg on two separate occasions is the diagnostic threshold. The term PIH has largely been replaced in clinical practice by more specific labels, chiefly “gestational hypertension” when high blood pressure occurs without other organ involvement, and “preeclampsia” when it appears alongside signs of organ damage such as protein in the urine, liver problems, or low platelets. Understanding the distinction matters because gestational hypertension can progress to preeclampsia, and the two carry different levels of risk for both mother and baby.

What Happens Inside the Placenta

During a healthy pregnancy, the blood vessels that supply the placenta undergo a dramatic remodeling. Spiral arteries in the uterus widen and lose much of their muscular wall so that blood flows freely to the developing baby. When that remodeling fails, the arteries stay narrow and stiff, restricting blood flow to the placenta. This poor remodeling is strongly linked to early-onset preeclampsia and several other serious pregnancy complications, including fetal growth restriction and placental abruption.¹ The restricted placenta then releases substances into the mother’s bloodstream that damage the lining of blood vessels throughout her body, driving blood pressure up and potentially harming the kidneys, liver, and brain.

This is why simply lowering blood pressure does not cure preeclampsia. The root problem is placental, not vascular, and the only definitive “cure” is delivery of the placenta. Every other treatment aims to buy time safely, keeping the mother stable long enough for the baby to mature.

Recognizing the Symptoms

Gestational hypertension itself is often silent. Many people first learn their blood pressure is elevated during a routine prenatal visit. That is one reason consistent prenatal care matters so much: without regular blood pressure checks, the condition can go undetected until it becomes severe.

When gestational hypertension progresses to preeclampsia, symptoms tend to appear. In a prospective study of women who progressed from gestational hypertension to preeclampsia, roughly nine out of ten had symptoms or clinical signs at the time of progression. Headache and blurred vision were the two most common neurological complaints. Other findings included liver dysfunction, severe hypertension, and, less frequently, kidney impairment and low platelet counts.²

Eye-related symptoms deserve special attention. A study of 120 women with pregnancy-related hypertension found that about a third experienced visual complaints, with blurring of vision being the most frequent, followed by flashing lights and double vision.³ These changes reflect the effect of high blood pressure on the tiny blood vessels of the retina and are considered warning signs that the condition is worsening. Any sudden visual disturbance during the second half of pregnancy warrants immediate evaluation.

Other red flags that should prompt urgent medical contact include:

• Severe headache: persistent and not relieved by usual pain relief
• Upper abdominal pain: especially under the right ribs, suggesting liver involvement
• Sudden swelling: particularly of the face and hands, beyond the normal mild ankle swelling of pregnancy
• Nausea or vomiting: appearing for the first time in the second half of pregnancy
• Decreased urine output: suggesting the kidneys are under strain

Who Is Most at Risk

Several factors raise the likelihood of developing hypertensive disorders during pregnancy, and they tend to compound one another.

Obesity is one of the strongest and most studied risk factors. Research has consistently shown that higher pre-pregnancy weight is independently linked to higher blood pressure during pregnancy. Some studies estimate that the risk of developing PIH is roughly three times greater in women with obesity, and the risk of preeclampsia doubles with every five-to-seven-unit increase in body mass index.⁴ This relationship is dose-dependent: the more severe the obesity, the steeper the risk climbs.

Pre-existing conditions also play a large role. Women with type 1 diabetes face a significantly elevated risk of preeclampsia at all gestational ages, and those with chronic hypertension before pregnancy are at even higher risk. Importantly, obesity remains an independent risk factor on top of these conditions; adjusting for weight does not make the other risks disappear, and vice versa.⁵

Other well-established risk factors include a first pregnancy, maternal age over 35, a personal or family history of preeclampsia, carrying multiples, and having had a pregnancy interval longer than ten years. These are the factors clinicians weigh when deciding who should receive preventive treatment such as low-dose aspirin.

When Gestational Hypertension Becomes Preeclampsia

Not every case of gestational hypertension stays as gestational hypertension. The overall rate of progression to preeclampsia is about 17%, but timing matters enormously. When hypertension is first diagnosed before 34 weeks, progression rates climb sharply, ranging from about 36% to 46% depending on the study. When hypertension appears after 34 weeks, the conversion rate drops to somewhere between 7% and 20%.⁶ A prospective cohort study confirmed a similar overall progression rate of about 17% and found that women who eventually developed preeclampsia had been diagnosed with gestational hypertension at earlier gestational ages than those who did not progress.²

This is why an early diagnosis of gestational hypertension triggers closer surveillance rather than reassurance. Blood pressure that first rises at 30 weeks carries a very different prognostic picture than blood pressure that first rises at 37 weeks.

How PIH Affects the Baby

The same placental dysfunction that raises the mother’s blood pressure can restrict the flow of nutrients and oxygen to the fetus. In a large study of over 4,400 women with hypertensive disorders of pregnancy, the overall rate of fetal growth restriction was about 15%. That figure rose to over 22% among women with severe preeclampsia and was considerably more common in preterm deliveries than term deliveries.⁷ After accounting for gestational age and other factors, preeclampsia and severe preeclampsia independently increased the risk of growth restriction and low birth weight.⁸

Growth restriction is not the only concern. Babies born to mothers with severe hypertensive disease are more likely to be delivered prematurely, either because the clinical situation requires it or because of spontaneous preterm labor. Prematurity brings its own cascade of potential complications, including breathing difficulties and need for intensive care.

Medications for Blood Pressure in Pregnancy

When blood pressure stays persistently elevated, medication may be necessary. Two drugs dominate the first-line conversation: labetalol (a combined alpha- and beta-blocker) and nifedipine (a calcium channel blocker). A randomized trial comparing the two in pregnant women with chronic hypertension found that both controlled average blood pressure to target levels equally well.⁹ A larger observational comparison also found no meaningful difference in their effectiveness at preventing adverse outcomes or in the rate of babies born small for gestational age.¹⁰

However, a target trial emulation found that nifedipine was associated with about a third higher risk of a composite of serious maternal outcomes, including higher rates of eclampsia and HELLP syndrome, compared with labetalol.¹¹ That study used a different design from the earlier trial, and its findings lean toward labetalol as a safer first choice for many women. This is an area of active clinical debate, and your provider’s recommendation will depend on your specific situation, side-effect profile, and any contraindications.

For acute crises, when blood pressure reaches 160/110 mmHg or higher and stays there, the standard approach involves intravenous medication alongside magnesium sulfate to prevent seizures. Early, standardized treatment of these critical elevations has been linked to reductions in eclampsia and severe complications.¹²

Aspirin for Prevention

Low-dose aspirin, typically 75 to 150 mg daily begun before 16 weeks, is one of the few interventions shown to reduce the risk of developing hypertensive disorders during pregnancy. The mechanism involves shifting the balance between two opposing hormones in a way that improves blood flow through the placenta and reduces blood vessel damage. A randomized trial in high-risk women in sub-Saharan Africa found that aspirin cut the incidence of hypertensive disorders by about 75% and significantly reduced early-onset preeclampsia and preterm birth.¹³ The concept itself dates back decades, with one of the earliest controlled trials in the 1980s showing that aspirin prevented PIH in high-risk first-time mothers.¹⁴

There is an important caveat. Aspirin’s benefit is strongest for women at risk of developing new preeclampsia. For women who already have chronic hypertension before pregnancy, a systematic review and meta-analysis found that low-dose aspirin did not significantly reduce the odds of developing superimposed preeclampsia on top of their existing condition.¹⁵ This distinction shapes who benefits most from aspirin prophylaxis and is something to discuss with a clinician who knows your history.

Exercise During Pregnancy

Physical activity is sometimes treated as an afterthought in conversations about PIH prevention, but the evidence is surprisingly strong. A meta-analysis of randomized trials found that women who engaged in aerobic exercise during early pregnancy for about 30 to 60 minutes, two to seven times per week, had a significantly lower incidence of gestational hypertensive disorders compared with controls.¹⁶ A review of additional trials confirmed that exercise interventions lowered the incidence of gestational hypertension, with the greatest benefit when exercise was supervised, low to moderate in intensity, and started in the first trimester.¹⁷

The type of exercise may matter too. Pooled data suggest that combining aerobic and resistance training, or practicing yoga alone, offered greater protection than aerobic exercise by itself.¹⁸ None of this means exercise is a guarantee against PIH, but it is one of the few modifiable factors with consistent trial support, and it carries the added benefit of reducing gestational diabetes risk.

Deciding When to Deliver

The central tension in managing PIH is balancing the risks of continuing the pregnancy against the risks of delivering early. Before 34 weeks, expectant management with close monitoring is usually preferred unless the situation becomes dangerous, because premature delivery carries serious neonatal risks. A trial in women with non-severe hypertensive disorders at 34 to 37 weeks found that immediate delivery reduced an already small risk of adverse maternal outcomes but significantly increased the risk of neonatal respiratory distress syndrome, making routine early delivery hard to justify at that gestational age.¹⁹

At term, the calculation shifts. A randomized trial in women with chronic or gestational hypertension who reached term found that planned delivery at around 38 weeks resulted in birth about six days earlier than usual care and did not increase adverse maternal or neonatal outcomes.²⁰ A separate study looking at delivery at 37 weeks versus 38 to 40 weeks for gestational hypertension found that waiting until 38 to 40 weeks was not associated with increased maternal problems but was tied to fewer neonatal complications and fewer admissions to intensive care compared with delivery at 37 weeks.²¹ Taken together, for women with uncomplicated gestational hypertension who remain stable, delivery around 38 to 39 weeks seems to hit a reasonable balance.

Newer Blood Tests That Help Sort Things Out

One of the hardest clinical problems with PIH is distinguishing a woman who will stay stable from one who is about to develop full preeclampsia. A blood test measuring two proteins involved in placental blood vessel formation has become increasingly useful here. The ratio of sFlt-1 to PlGF, measured in the mother’s blood, reflects the balance between substances that promote and inhibit blood vessel growth in the placenta. When the ratio is low (38 or below in a widely used cutoff), the chance of developing preeclampsia within the next week is extremely small, with a negative predictive value over 99%.²² This test is most valuable for ruling out preeclampsia in the short term, allowing clinicians to safely send some women home rather than admitting them for observation.²³

When the ratio is elevated, it correlates with earlier delivery, lower birth weight, lower newborn health scores, and a higher chance of neonatal intensive care admission.²⁴ It is not yet standard everywhere, but its use is growing, particularly in European settings, and it represents a meaningful step toward more precise management of suspected preeclampsia.

Blood Pressure After Delivery

A common misconception is that blood pressure normalizes quickly once the baby arrives. In reality, many women remain hypertensive for days or weeks after delivery. A large study found that about 82% of women who had a hypertensive disorder during pregnancy still had elevated blood pressure after hospital discharge. Roughly 14% had severe postpartum hypertension. More than half were sent home without blood pressure medication, and among those who did eventually start medication after discharge, the typical start date was about a week postpartum.²⁵

This finding underscores the need for blood pressure monitoring in the weeks after delivery, not just during pregnancy. If you had PIH or preeclampsia, ask about a plan for postpartum blood pressure checks before you leave the hospital. Some facilities now use home monitoring devices or telehealth check-ins to catch postpartum blood pressure spikes. Research suggests that home blood pressure monitoring in hypertensive pregnancies can reduce the number of hospital visits without compromising safety.²⁶ A broader research program studying self-monitoring in higher-risk and hypertensive pregnancies found the approach was feasible, safe, and no more expensive than standard care, though it did not improve detection rates beyond what regular clinic visits achieved.²⁷

Long-Term Cardiovascular Risk

Hypertensive disorders of pregnancy are no longer considered a condition that ends when the pregnancy does. A study tracking women over years found that those who had experienced a hypertensive disorder of pregnancy had about 7 cardiovascular events per 1,000 women-years, compared with roughly 5 per 1,000 among those who had not, a statistically significant difference. The risk of coronary artery disease was nearly doubled, and the risk of heart failure was about 70% higher. Perhaps most striking, chronic hypertension appearing after the pregnancy accounted for the majority of the increased heart disease risk, explaining about 64% of the association with coronary artery disease and about half of the association with heart failure.²⁸

This means that a history of PIH or preeclampsia is essentially an early warning signal for future cardiovascular disease. Professional organizations now recommend that women with this history undergo regular cardiovascular screening in the years and decades that follow. Keeping blood pressure, weight, and cholesterol in check after a hypertensive pregnancy is not generic advice; it is targeted prevention based on known elevated risk.

Racial and Ethnic Disparities

The burden of hypertensive disorders in pregnancy is not distributed equally. A large California-based study found that Black mothers had about 60% higher risk of hypertensive disorders of pregnancy compared with white mothers, and more than double the risk of chronic hypertension in pregnancy.²⁹ These are not just differences in diagnosis rates; they translate to worse outcomes. A national analysis found that the percentage of severe obstetric morbidity attributable to chronic hypertension was roughly three times higher in Black women than in white women. Native Hawaiian and Other Pacific Islander women also faced disproportionately elevated risks for complications including stillbirth and extremely preterm birth.³⁰

These disparities reflect a tangle of factors including structural inequities in healthcare access, differences in the prevalence of underlying conditions like chronic hypertension and obesity, the physiological impact of chronic stress, and variations in the quality of care received. Addressing them requires systemic change rather than individual behavior modification, but awareness is a starting point. If you belong to a higher-risk group, more assertive screening and earlier preventive interventions like low-dose aspirin may be especially worthwhile conversations to have with your prenatal care provider.